Hyperuricemia - Pipeline Review, H1 2018

  • ID: 4482746
  • Drug Pipelines
  • 62 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CymaBay Therapeutics Inc
  • Nippon Chemiphar Co Ltd
  • Nobelpharma Co Ltd
  • Teijin Pharma Ltd
  • MORE
Hyperuricemia - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H1 2018, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 5, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CymaBay Therapeutics Inc
  • Nippon Chemiphar Co Ltd
  • Nobelpharma Co Ltd
  • Teijin Pharma Ltd
  • MORE
Introduction

Report Coverage

Hyperuricemia - Overview

Hyperuricemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hyperuricemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hyperuricemia - Companies Involved in Therapeutics Development

Allena Pharmaceuticals Inc

CymaBay Therapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

Nippon Chemiphar Co Ltd

Nobelpharma Co Ltd

Polaris Pharmaceuticals Inc

Teijin Pharma Ltd

Hyperuricemia - Drug Profiles

ALLN-346 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

allopurinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arhalofenate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

febuxostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FYU-981 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSA-Uricase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JPH-367 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NC-2500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NC-2700 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPCX-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegadricase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-4640 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEI-A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMX-049 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hyperuricemia - Dormant Projects

Hyperuricemia - Discontinued Products

Hyperuricemia - Product Development Milestones

Featured News & Press Releases

Nov 29, 2017: Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects; NC-2500 Shows Favorable Profile to Lower Serum Uric Acid in Phase-1 Study

Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat

Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit

Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricemia and Predicts Savings for NHS Scotland

May 23, 2016: Teijin Pharma’s Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia

Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 -

Jun 30, 2015: New Indication for Teijin Pharma’s Febuxostat in Europe

Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat

Nov 05, 2013: Teijin Pharma files patent infringement suit against Dr Reddy's

Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric

Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat

Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat

Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea

May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan

Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hyperuricemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hyperuricemia - Pipeline by Allena Pharmaceuticals Inc, H1 2018

Hyperuricemia - Pipeline by CymaBay Therapeutics Inc, H1 2018

Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Hyperuricemia - Pipeline by Nippon Chemiphar Co Ltd, H1 2018

Hyperuricemia - Pipeline by Nobelpharma Co Ltd, H1 2018

Hyperuricemia - Pipeline by Polaris Pharmaceuticals Inc, H1 2018

Hyperuricemia - Pipeline by Teijin Pharma Ltd, H1 2018

Hyperuricemia - Dormant Projects, H1 2018

Hyperuricemia - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Hyperuricemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allena Pharmaceuticals Inc
  • CymaBay Therapeutics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Nippon Chemiphar Co Ltd
  • Nobelpharma Co Ltd
  • Polaris Pharmaceuticals Inc
  • Teijin Pharma Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll